Unresectable Solid Tumor
14
11
11
2
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 14 trials
100.0%
+13.5% vs benchmark
0%
0 trials in Phase 3/4
0%
0 of 2 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (14)
Study of RGT-490 in Patients With PIK3CA-Mutated Advanced Solid Tumors
A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors
Palliative Spatially Fractionated (GRID) Radiotherapy Using Intensity Modulated Proton Therapy
A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation
Pemigatinib + Afatinib in Advanced Refractory Solid Tumors
A Dose Escalation and Expansion Study of [177Lu]Lu-SN201 in Participants With Advanced Cancer
First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer
CSB-321 Ph 1 in Immunotherapy for the Treatment of Cancer
A Beta-only IL-2 ImmunoTherapY Study
First-in-Human Study of RLY-5836 in Advanced Breast Cancer and Other Solid Tumors
A Multicenter Study of Avapritinib Efficacy and Safety of Metastatic or Unresectable Gastrointestinal Stromal Tumors
Avapritinib in the Treatment of Unresectable or Recurrent Metastatic GIST Non-exon18 Mutations of PDGFRA
COLDFIRE-III Trial: Efficacy of Irreversible Electroporation and Stereotactic Body Radiotherapy for Perivascular and Peribiliary Colorectal Liver Metastases
A Study of RC118 in Patients With Locally Advanced Unresectable/Metastatic Solid Tumours